Alzamend Neuro, Inc. (ALZN)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Quarterly Financials
| Metric | 2025-07-31 | 2025-10-31 | 2026-01-31 | 2026-04-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (2.7M) | (998K) | (2.2M) | (2.9M) |
| Net Income | (2.7M) | (1.0M) | (2.2M) | (2.9M) |
| Diluted EPS | $-1.28 | $-0.30 | $-0.58 | N/A |
Annual Financials
| Metric | 2023-04-30 | 2024-04-30 | 2025-04-30 | 2026-04-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (14.9M) | (9.9M) | (4.5M) | (8.8M) |
| Net Income | (14.9M) | (9.9M) | (4.5M) | (8.8M) |
| Diluted EPS | $-228.90 | $-132.33 | $-11.32 | $-2.63 |